Top Markets
#1 Glidr Glidr +51.75%
#2 Akedo Akedo +49.85%
#3 DOVU DOVU +47.86%
#4 Velvet Velvet +43.76%
#5 Black Phoenix Black Phoenix +34.36%
#6 Cross Cross +21.02%
#7 Perle Perle +19.03%
#8 τemplar τemplar +16.86%
#9 Cysic Cysic +15.93%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +15.88%
Coin of the day
Glidr Glidr
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Chimeric Therapeutics Limited Chimeric Therapeutics Limited

Chimeric Therapeutics Limited

CHM
Rang in aandelen #38385
Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical... Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical firm dedicated to developing and commercializing a diverse array of cell therapies designed to combat various cancers. Its lead natural killer (NK) cell platform, CHM 0201, is currently undergoing Phase I clinical evaluation for both solid tumors and hematological malignancies. Another key candidate, CHM 1101 (a CLTX CAR T therapy), is also in Phase I trials, specifically targeting recurrent or progressive glioblastoma in patients expressing MMP2+. Beyond these, the company's development pipeline encompasses CHM 0301 for blood cancers; CLTX CAR NK (CHM 1301) and CDH17 CAR NK (CHM 2301) for solid tumors. The CLTX CAR T platform (CHM 1101) is additionally being investigated for melanoma, colorectal, and prostate cancers, while CDH17 CAR T (CHM 2101) is being developed for neuroendocrine, colorectal, pancreatic, and gastric cancers. Chimeric Therapeutics, headquartered in Carlton, Australia, was founded in 2020.
Aandeelprijs
$0.02468497
Marktkapitalisatie
$1.01M
Verandering (1 dag)
-12.50%
Verandering (1 jaar)
-87.34%
Land
AU
Handel Chimeric Therapeutics Limited (CHM)

Categorie

Healthcare
P/B-ratio voor Chimeric Therapeutics Limited (CHM)
P/B-ratio op 2026 TTM: 0
Volgens de meest recente financiële rapporten en aandelenkoers van Chimeric Therapeutics Limited is de huidige P/B-ratio (TTM) 0. Eind 2026 had het bedrijf een P/B-ratio van 0.
P/B-ratiohistoriek voor Chimeric Therapeutics Limited van 2026 tot 2026
P/B-ratio aan het einde van elk jaar
Jaar P/B-ratio Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
P/B-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/B-ratio Verschil in P/B-ratio Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 -
BE